GlassScriptPhysician profile
Min S Pak
NPI 1962438317
$10,501.90
in general payments reported to CMS, 2019-2025
55 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $1,043 · 2021: $1,628 · 2022: $1,779 · 2023: $1,376 · 2024: $1,374 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,414.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,559.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,014.29 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $878.48 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $859.49 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $667.03 | 2019-2025 | |
| Lilly USA, LLC | $563.20 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $422.83 | 2019-2024 | |
| Amgen INC. | $401.65 | 2019-2024 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $401.64 | 2019-2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $375.04 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $336.19 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $325.68 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $271.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $264.16 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.09 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Pak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.